CVasThera

Recent Finacing

Equity

Recent Raise

$1.6M

CVasThera develops therapeutics for cardiovascular and bowel diseases, holds exclusive licenses from INSERM/École des Mines/GALA, and is advancing lead candidate CVT120165 toward a Phase II trial in Crohn’s disease.

Founded 2016

Midi-Pyrenees, France

1-10

Private

cvasthera.com

Highlights

Focus Areas

Biotechnology

Pharmaceutical

Recent Investors

A

Financials

$1.6M

Total Raised

1

Funding round

4

Investors

Team

Upgrade to view the team

See the team members at CVasThera.